Seeking Alpha

BioCryst advances two new plasma kallikrein inhibitors in quest for HAE prophylactic

  • BioCryst (BCRX) continues to work towards finding novel treatment options for HAE, as the company advances two optimized plasma kallikrein inhibitors into preclinicals.
  • The two candidates improved selectivity and bioavailability compared to BCX-4161 with "no effect on prothrombin time at high concentrations." (PR)
  • BCRX +7.5% premarket
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector